OMEROS CORP Notes Payable, Noncurrent
OMEROS CORP (OMER) had Notes Payable, Noncurrent of $8.68 million as of 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities › Notes Payable, Noncurrent
us-gaap:LongTermNotesPayable · last filed 2012-11-09
- 2012-09-30: Notes Payable, Noncurrent $8.68M.
- 2012-06-30: Notes Payable, Noncurrent $10.35M.
- 2012-03-31: Notes Payable, Noncurrent $11.97M.
- 2011-12-31: Notes Payable, Noncurrent $13.55M.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2012-09-30 | $8.68M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $10.35M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $11.97M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $13.55M 10-Q · filed 2012-11-09 |
| 2011-09-30 | $15.09M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $16.59M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $9.86M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |